Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03093428
Title Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC
Recruitment Active, not recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute

prostate adenocarcinoma


Pembrolizumab + Radium Ra 223 dichloride

Radium Ra 223 dichloride

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.